Craif's urine cancer test 'mySignal Scan' certified as Kanagawa Prefecture's 'ME-BYO BRAND'
Craif's urine cancer test has been certified as a 'ME-BYO BRAND' by Kanagawa Prefecture.
📋 Article Processing Timeline
- 📰 Published: March 28, 2026 at 16:50
- 🔍 Collected: March 28, 2026 at 21:59 (5h 9m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 07:59 (417h 59m after Collected)
Bio-AI startup Craif Inc. (Headquarters: Shinjuku-ku, Tokyo; CEO: Ryuichi Onose; hereinafter 'Craif') is pleased to announce that its urine cancer test, 'mySignal Scan,' has been certified as a 'ME-BYO BRAND' by Kanagawa Prefecture.
Craif provides testing services that enable early cancer detection through its proprietary bio-AI technology, which analyzes microRNA in urine. 'mySignal Scan' is a test kit that allows for the highly accurate and convenient assessment of 10 types of cancer risk, starting from stage 1, using a non-invasive urine sample. With this 'ME-BYO BRAND' certification, we aim to further promote our efforts toward early cancer detection and optimized treatment, striving to achieve our mission: 'Realizing a society where people can live out their natural lifespans.'
■ About 'ME-BYO BRAND'
'ME-BYO BRAND' is a certification system established in 2015 as part of Kanagawa Prefecture's initiatives to improve 'Me-byo' (the state between health and illness). The prefecture certifies excellent products and services that contribute to the visualization and improvement of Me-byo, thereby promoting Me-byo improvement and the expansion of the Me-byo industry.
The certification targets products and services based on scientific evidence that contribute to the visualization of Me-byo and the resolution of social issues, leading to changes in awareness and behavior among residents. Evaluations are based on five criteria: conceptual alignment, reliability, innovation, marketability, and future potential.
ME-BYO BRAND:
https://www.pref.kanagawa.jp/docs/mv4/cnt/f531787/p1078097.html
■ About 'mySignal Scan'
'mySignal Scan' is a test that extracts microRNA from urine and analyzes it using AI to evaluate the risk of 10 types of cancer*, including pancreatic cancer, by cancer type, starting from stage 1. It allows for non-invasive testing simply by collecting a urine sample.
For more details, please visit our website.